CN114630832A - 一种嘧啶并环衍生物及其在医药上的应用 - Google Patents

一种嘧啶并环衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN114630832A
CN114630832A CN202080061791.2A CN202080061791A CN114630832A CN 114630832 A CN114630832 A CN 114630832A CN 202080061791 A CN202080061791 A CN 202080061791A CN 114630832 A CN114630832 A CN 114630832A
Authority
CN
China
Prior art keywords
alkyl
cyano
alkoxy
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080061791.2A
Other languages
English (en)
Inventor
张晨
何平
魏琦
王健民
钱国飞
叶飞
唐平明
李瑶
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN114630832A publication Critical patent/CN114630832A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

本发明涉及通式(I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、共晶或药学上可接受的盐。本发明还涉及所述化合物的中间体和制备方法，以及在制备预防或治疗与KRAS G12C活性或表达量相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202080061791.2A 2019-11-15 2020-11-11 一种嘧啶并环衍生物及其在医药上的应用 Pending CN114630832A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CN201911115896 2019-11-15
CN2019111158967 2019-11-15
CN201911293807 2019-12-18
CN2019112938078 2019-12-18
CN2020103860217 2020-05-09
CN202010386021 2020-05-09
CN202010499217 2020-06-05
CN2020104992177 2020-06-05
CN202010609971 2020-06-30
CN2020106099711 2020-06-30
CN2020112001496 2020-11-03
CN202011200149 2020-11-03
PCT/CN2020/128033 WO2021093758A1 (zh) 2019-11-15 2020-11-11 一种嘧啶并环衍生物及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN114630832A true CN114630832A (zh) 2022-06-14

Family

ID=75911780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080061791.2A Pending CN114630832A (zh) 2019-11-15 2020-11-11 一种嘧啶并环衍生物及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN114630832A (zh)
TW (1) TWI760919B (zh)
WO (1) WO2021093758A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
WO2021086833A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
BR112022012106A2 (pt) 2019-12-20 2022-09-20 Mirati Therapeutics Inc Inibidores de sos1
WO2021139748A1 (en) * 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
WO2022040469A1 (en) * 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685502A (zh) * 2020-12-25 2022-07-01 由理生物医药（上海）有限公司 作为kras-g12c抑制剂的螺环类化合物
CN114805311A (zh) * 2021-01-21 2022-07-29 苏州亚盛药业有限公司 螺环茚
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023143623A1 (zh) * 2022-01-30 2023-08-03 上海医药集团股份有限公司 一种喹啉类化合物及其应用
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288045A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US20160297774A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN109843856A (zh) * 2016-05-18 2019-06-04 米拉蒂治疗股份有限公司 Kras g12c抑制剂
CN110036010A (zh) * 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
US20190248767A1 (en) * 2018-02-09 2019-08-15 Pfizer Inc. Tetrahydroquinazoline Derivatives Useful as Anticancer Agents
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN112119075A (zh) * 2018-08-16 2020-12-22 豪夫迈·罗氏有限公司 稠环化合物
CN113087700A (zh) * 2020-01-08 2021-07-09 苏州亚盛药业有限公司 螺环四氢喹唑啉
CN114096544A (zh) * 2019-05-20 2022-02-25 加州理工学院 Kras g12c抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659021B (zh) * 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
EP3377481A1 (en) * 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288045A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US20160297774A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN109843856A (zh) * 2016-05-18 2019-06-04 米拉蒂治疗股份有限公司 Kras g12c抑制剂
CN110036010A (zh) * 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
US20190248767A1 (en) * 2018-02-09 2019-08-15 Pfizer Inc. Tetrahydroquinazoline Derivatives Useful as Anticancer Agents
TW201942116A (zh) * 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
CN112119075A (zh) * 2018-08-16 2020-12-22 豪夫迈·罗氏有限公司 稠环化合物
CN114096544A (zh) * 2019-05-20 2022-02-25 加州理工学院 Kras g12c抑制剂及其用途
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN113087700A (zh) * 2020-01-08 2021-07-09 苏州亚盛药业有限公司 螺环四氢喹唑啉

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
叶炜芃等: "奥沙利铂或伊立替康联合氟尿嘧啶在 KRAS 突变型的晚期结直肠癌一线化疗中的疗效比较", 《岭南现代临床外科》, vol. 16, no. 5, pages 553 - 556 *

Also Published As

Publication number Publication date
WO2021093758A1 (zh) 2021-05-20
TWI760919B (zh) 2022-04-11
TW202128672A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
CN114630832A (zh) 一种嘧啶并环衍生物及其在医药上的应用
TWI718207B (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
EP2496559B1 (en) Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline and their use as hsd 1 inhibitors
WO2021219072A1 (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
EP2215079B1 (en) Inhibitors of c-fms kinase
JP6522646B2 (ja) ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
TW200800908A (en) Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
TW202220985A (zh) 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021249057A1 (zh) 杂环化合物及其用途
CN115304623A (zh) 一种嘧啶并环衍生物及其在医药上的应用
JP2017508779A5 (zh)
KR20230002419A (ko) Bcl-2 억제제
TW202214639A (zh) 吡啶酮并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN115867540A (zh) 硝羟喹啉衍生物及其制备方法和用途
WO2020168927A1 (zh) 含氮并环化合物、其制备方法及用途
WO2020182018A1 (zh) 氮杂环化合物、其制备方法及用途
WO2023143424A1 (zh) 一种氮杂并环衍生物及其在医药上的应用
CN112771047A (zh) 作为RET激酶抑制剂的取代的咪唑[1,2-a]吡啶和[1,2,4]***[1,5-a]吡啶化合物
WO2023016518A1 (zh) 一种杂环衍生物及其组合物和药学上的应用
CN114805303A (zh) 一种具有降解egfr双功能分子及其组合物和药学上的应用
CN107849047A (zh) 一种联苯衍生物及其制备方法和在医药上的用途
CN111801318B (zh) 受体抑制剂、包含其的药物组合物及其用途
Ihara et al. Studies on the syntheses of heterocyclic compounds and natural products. 999. Double enamine annelation of 3, 4-dihydro-1-methyl-. beta.-carboline and isoquinoline derivatives with 6-methyl-2-pyrone-3, 5-dicarboxylates and its application for the synthesis of (.+-.)-camptothecin
WO2020192652A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination